SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (292)8/28/2002 2:12:45 PM
From: Biomaven  Read Replies (1) of 508
 
quid,

This is a very interesting issue - why the improved mortality given not much improvement in FVC or A-a gradient compared with placebo? We may know more once we see the details, until then we (and the company) can only speculate.

It would appear to me that the drug must have some impact that is not being measured by these two tests. Response to infection is certainly one possibility given that IFN-gamma is an immune modulator. One other possibility is that the measured FVC improvement lags the "real" improvement in lung function. Note there was symptom improvement at the end of the trial - I missed what the p value on this was.

The 10% advantage on the endpoint is relative to placebo - in other words maybe 70% of placebo patients "progressed" (meaning FVC or A-a gradient increased by more than the thresholds or the patient died) whereas only 60% of drug patients progressed.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News